Cenk Yasa, Ozguc Takmaz, Ozlem Dural, Suleyman Engin Akhan
Gynecology and Obstetric Department, Istanbul Medical School, Istanbul University, Istanbul, Turkey.
DOI: 10.4236/jct.2013.45110   PDF    HTML   XML   8,250 Downloads   14,659 Views   Citations

Abstract

Endometrial cancer is the most common gynecologic malignancy in more developed countries. Most endometrial carcinomas cases are diagnosed at an early stage with a tumor confined to the uterine corpus. Although most patients are cured by surgery alone, about 15% - 20% with no signs of locally advanced or metastatic disease at primary treatment recurs, with limited responsiveness to systemic therapy. Although it has a comparatively low mortality rate compared with other gynaecological cancers, it is capable of aggressive behaviour. Diagnosis at an early stage is the most important determinant of survival. Discovery of new diagnostic biomarkers/panels for early diagnosis of endometrial cancer is one of the main challenges of modern medicine. For endometrial cancers, there are no established serum markers. We will review the present knowledge regarding tumor markers, assessing how such markers could be applied to address in screening, diagnosis and monitoring of endometrial carcinoma.

Keywords

Endometrial Cancer; Tumor Markers

Share and Cite:

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray and M. J. Thun, “Cancer Statistics, 2008,” CA: A Cancer Journal for Clinicians, Vol. 58, No. 2, 2008, pp. 71-96. doi:10.3322/CA.2007.0010
[2]	V. E. von Gruenigen, K. M. Gil, H. E. Frasure, E. L. Jenison and M. P. Hopkins, “The Impact of Obesity and Age on Quality of Life in Gynecologic Surgery,” American Journal of Obstetrics & Gynecology, Vol. 193, No. 4, 2005, pp. 1369-1375. doi:10.1016/j.ajog.2005.03.038
[3]	F. Bray, A. H. Loos, M. Oostindier and E. Weiderpass, “Geographic and Temporal Variations in Cancer of the Corpus Uteri: Incidence and Mortality in Preand Postmenopausal Women in Europe,” International Journal of Cancer, Vol. 20, No. 117, 2005, pp. 123-131. doi:10.1002/ijc.21099
[4]	J. V. Bokhman, “Two Pathogenetic Types of Endometrial Carcinoma,” Gynecologic Oncology, Vol. 15, No. 1, 1983, pp. 10-17. doi:10.1016/0090-8258(83)90111-7
[5]	B. A. Goff, D. Kato, R. A. Schmidt, M. Ek, J. A. Ferry, H. G. Muntz, J. M. Cain, H. K. Tamimi, D. C. Figge and B. E. Greer, “Uterine Papillary Serous Carcinoma: Patterns of Metastatic Spread,” Gynecologic Oncology, Vol. 54, No. 3, 1994, pp. 264-268. doi:10.1006/gyno.1994.1208
[6]	K. Garg and R. A. Soslow, “Lynch Syndrome (Hereditary Non-Polyposis Colorectal Cancer) and Endometrial Carcinoma,” Journal of Clinical Pathology, Vol. 62, No 8, 2009, pp. 679-684. doi:10.1136/jcp.2009.064949
[7]	E. Weiderpass, I. Persson, H. O. Adami, C. Magnusson, A. Lindgren and J. A. Baron, “Body Size in Different Periods of Life, Diabetes Mellitus, Hypertension, and Risk of Postmenopausal Endometrial Cancer (Sweden),” Cancer Causes & Control, Vol.11, No. 2, 2000, pp. 185-192. doi:10.1023/A:1008946825313
[8]	G. Kvale, I. Heuch and G. Ursin, “Reproductive Factors and Risk of Cancer of the Uterine Corpus: A Prospective Study,” Cancer Research, Vol. 48, No. 21, 1988, pp. 6217-6221.
[9]	P. Neven and I. Vergote, “Should Tamoxifen Users Be Screened for Endometrial Lesions?” Lancet, Vol. 17, No. 351, 1998, pp. 155-157. doi:10.1016/S0140-6736(05)78216-7
[10]	Y. Ueda, T. Enomoto, T. Kimura, T. Miyatake, K. Yoshino, M. Fujita and T. Kimura, “Serum Biomarkers for Early Detection of Gynecologic Cancers,” Cancers, Vol. 2, No. 2, 2010, pp. 1312-1327. doi:10.3390/cancers2021312
[11]	R. C. Bast Jr., S. Knauf, A. Epenetos, B. Dhokia, L. Daly, M. Tanner, J. Soper, W. Creasman, S. Gall, R. C. Knapp, et al., “Coordinate Elevation of Serum Markers in Ovarian Cancer But Not in Benign Disease,” Cancer, Vol. 15, No. 68, 1991, pp. 1758-1763. doi:10.1002/1097-0142(19911015)68:8<1758::AID-CNCR2820680819>3.0.CO;2-#
[12]	I. Jacobs and R. C. Bast Jr., “The CA 125 Tumour-Associated Antigen: A Review of the Literature,” Human Reproduction, Vol. 4, No. 1, 1989, pp. 1-12.
[13]	M. H. Vuento, U. H. Stenman, J. P. Pirhonen, J. I. Makinen, P. J. Laippala and T. A. Salmi, “Significance of a Single CA 125 Assay Combined with Ultrasound in the Early Detection of Ovarian and Endometrial Cancer,” Gynecologic Oncology, Vol. 64, No. 1, 1997, pp. 141-146. doi:10.1006/gyno.1996.4545
[14]	G. Scambia, A. Gadducci, P. B. Panici, E. Foti, M. Ferdeghini, G. Ferrandina, M. Amoroso, C. Castellani, V. Facchini and S. Mancuso, “Combined Use of CA 125 and CA 15-3 in Patients with Endometrial Carcinoma,” Gynecologic Oncology, Vol. 54, No. 3, 1994, pp. 292-297. doi:10.1006/gyno.1994.1213
[15]	A. Hakala, B. M. Kacinski, E. R. Stanley, E. I. Kohorn, U. Puistola, J. Risteli, L. Risteli, C. Tomás and A. Kauppila, “Macrophage Colony-Stimulating Factor 1, a Clinically Useful Tumor Marker in Endometrial Adenocarcinoma: Comparison with CA 125 and the Aminoterminal Propeptide of Type III Procollagen,” American Journal of Obstetrics & Gynecology, Vol. 173, No. 1, 1995, pp. 112-119. doi:10.1016/0002-9378(95)90178-7
[16]	P. L. Cherchi, S. Dessole, G. A. Ruiu, G. Ambrosini, M. Farina, G. Capobianco and A. Ambrosini, “The Value of Serum CA 125 and Association CA 125/CA 19-9 in Endometrial Carcinoma,” European Journal of Gynaecological Oncology, Vol. 20, No. 4, 1999, pp. 315-317.
[17]	S. Ginath, J. Menczer, Y. Fintsi, E. Ben-Shem, M. Glezerman and I. Avinoach, “Tissue and Serum CA 125 Expression in Endometrial Cancer,” International Journal of Gynecological Cancer, Vol. 12, No. 4, 2002, pp. 372-375. doi:10.1046/j.1525-1438.2002.01007.x
[18]	H. H. Chung, J. W. Kim, N. H. Park, Y. S. Song, S. B. Kang and H. P. Lee, “Use of Preoperative Serum CA-125 Levels for Prediction of Lymph Node Metastasis and Prognosis in Endometrial Cancer,” Acta Obstetricia et Gynecologica Scandinavica, Vol. 85, No. 12, 2006, pp. 1501-1505. doi:10.1080/00016340601022777
[19]	E. P. Beck, M. Wagner, L. Anselmino, F. Xu, R. C. Bast Jr. and W. Jaeger, “Is OVX1 a Suitable Marker for Endometrial Cancer?” Gynecologic Oncology, Vol. 65, No. 2, 1997, pp. 291-296. doi:10.1006/gyno.1997.4620
[20]	T. Kurihara, H. Mizunuma, M. Obara, K. Andoh, Y. Ibuki and T. Nishimura, “Determination of a Normal Level of Serum CA 125 in Postmenopausal Women as a Tool for Preoperative Evaluation and Postoperative Surveillance of Endometrial Carcinoma,” Gynecologic Oncology, Vol. 69, No. 3, 1998, pp. 192-196. doi:10.1006/gyno.1998.5018
[21]	M. Takami, H. Sakamoto, K. Ohtani, T. Takami and K. Satoh, “An Evaluation of CA125 Levels in 291 Normal Postmenopausal and 20 Endometrial AdenocarcinomaBearing Women before and after Surgery,” Cancer Letters, Vol. 16, No. 121, 1997, pp. 69-72. doi:10.1016/S0304-3835(97)00332-7
[22]	A. K. Sood, R. E. Buller, R. A. Burger, J. D. Dawson, J. I. Sorosky and M. Berman, “Value of Preoperative CA 125 Level in the Management of Uterine Cancer and Prediction of Clinical Outcome,” Obstetrics & Gynecology, Vol. 90, No. 3, 1997, pp. 441-447. doi:10.1016/S0029-7844(97)00286-X
[23]	A. Yildiz, H. Yetimalar, B. Kasap, C. Aydin, S. Tatar, F. Soylu, F. S. Yildiz, “Preoperative Serum CA 125 Level in the Prediction of the Stage of Disease in Endometrial Carcinoma,” The European Journal of Obstetrics & Gynecology and Reproductive Biology, Vol. 164, No. 2, 2012, pp. 191-195. doi:10.1016/j.ejogrb.2012.05.038
[24]	A. Gadducci, S. Cosio, A. Carpi, A. Nicolini and A. R. Genazzani, “Serum Tumor Markers in the Management of Ovarian, Endometrial and Cervical Cancer,” Biomedicine & Pharmacotherapy, Vol. 58, No. 1, 2004, pp. 24-38. doi:10.1016/j.biopha.2003.11.003
[25]	P. M. Carpenter, G. P. Gamboa, G. E. Dorion, N. S. Ramsinghani, A. M. A?ssi and A. Manetta, “Radiation-Induced CA 125 Production by Mesothelial Cells,” Gynecologic Oncology, Vol. 63, No. 3, 1996, pp. 328-332. doi:10.1006/gyno.1996.0331
[26]	S. S. Lo, D. K. Cheng, T. Y. Ng, L. C. Wong, H. Y. Ngan, “Prognostic Significance of Tumour Markers in Endometrial Cancer,” Tumor Biology, Vol. 18, No. 4, 1997, pp. 241-249. doi:10.1159/000218037
[27]	M. S. Lundstrom, C. K. Hogdall, A. L. Nielsen and H. C. Nyholm, “Serum Tetranectin and CA 125 in Endometrial Adenocarcinoma,” Anticancer Research, Vol. 20, No. 5, 2000, pp. 3903-3906.
[28]	F. V. Price, S. K. Chambers, M. L. Carcangiu, E. I. Kohorn, P. E. Schwartz, J. T. Chambers, “CA 125 May Not Reflect Disease Status in Patients with Uterine Serous Carcinoma,” Cancer, Vol. 82, No. 9, 1998, pp. 1720-1725. doi:10.1002/(SICI)1097-0142(19980501)82:9<1720::AID-CNCR19>3.0.CO;2-6
[29]	D. Abramovich, M. Markman, A. Kennedy, K. Webster and J. Belinson, “Serum CA-125 as a Marker of Disease Activity in Uterine Papillary Serous Carcinoma,” Journal of Cancer Research and Clinical Oncology, Vol. 125, No. 12, 1999, pp. 697-698. doi:10.1007/s004320050336
[30]	M. Sawada, Y. Okudaira, Y. Matsui and Y. Shimizu, “Immunosuppressive Acidic Protein in Patients with Gynecologic Cancer,” Cancer, Vol. 15, No. 54, 1984, pp. 652-656. doi:10.1002/1097-0142(1984)54:4<652::AID-CNCR2820540411>3.0.CO;2-C
[31]	N. Takeshima, Y. Shimizu, S. Umezawa, Y. Hirai, J. T. Chen, I. Fujimoto, K. Yamauchi and K. Hasumi, “Combined Assay of Serum Levels of CA 125 and CA 19-9 in Endometrial Carcinoma,” Gynecologic Oncology, Vol. 54, No. 3, 1994, pp. 321-326. doi:10.1006/gyno.1994.1217
[32]	H. Hareyama, N. Sakuragi, S. Makinoda and S. Fujimoto, “Serum and Tissue Measurements of CA 72-4 in Patients with Endometrial Carcinoma,” Journal of Clinical Pathology, Vol. 49, No. 12, 1996, pp. 967-970. doi:10.1136/jcp.49.12.967
[33]	A. Gadducci, M. Ferdeghini, C. Prontera, P. Giordano, R. Cristofani, R. Bianchi and P. Fioretti, “A Comparison of Pretreatment Serum Levels of Four Tumor Markers in Patients with Endometrial and Cervical Carcinoma,” European Journal of Gynaecological Oncology, Vol. 11, No. 4, 1990, pp. 283-288.
[34]	C. S. Diefenbach, Z. Shah, A. Iasonos, R. R. Barakat, D. A. Levine, C. Aghajanian, P. Sabbatini, M. L. Hensley, J. Konner, W. Tew, D. Spriggs, M. Fleisher, H. Thaler and J. Dupont, “Preoperative Serum YKL-40 Is a Marker for Detection and Prognosis of Endometrial Cancer,” Gynecologic Oncology, Vol. 104, No. 2, 2007, pp. 435-442. doi:10.1016/j.ygyno.2006.08.028
[35]	R. G. Moore, A. K. Brown, M. C. Miller, D. Badgwell, Z. Lu, W. J. Allard, C. O. Granai, R. C. Bast Jr. and K. Lu, “Utility of a Novel Serum Tumor Biomarker HE4 in Patients with Endometrioid Adenocarcinoma of the Uterus,” Gynecologic Oncology, Vol. 110, No. 2, 2008, pp. 196-201. doi:10.1016/j.ygyno.2008.04.002
[36]	M. Suzuki, M. Ohwada, I. Sato and M. Nagatomo, “Serum Level of Macrophage Colony-Stimulating Factor as a Marker for Gynecologic Malignancies,” Oncology, Vol. 52, No. 2, 1995, pp. 128-133. doi:10.1159/000227443
[37]	R. Konno, T. Takano, S. Sato and A. Yajima, “Serum Soluble Fas Level as a Prognostic Factor in Patients with Gynecological Malignancies,” Clinical Cancer Research, Vol. 6, No. 9, 2000, pp. 3576-3580.
[38]	B. Dobrzycka, S. J. Terlikowski, M. Kwiatkowski, M. Garbowicz, M. Kinalski and L. Chyczewski “Prognostic Significance of VEGF and Its Receptors in Endometrioid Endometrial Cancer,” Ginekologia Polska, Vol. 81, No. 6, 2010, pp. 422-425.